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Abstract
Background
Serum total cholesterol is one of the major targets for cardiovascular disease prevention.
Statins are effective for cholesterol control in individual patients. At the population level,
however, their contribution to total cholesterol decline remains unclear. The aim of this
study was to quantify the contribution of statins to the observed fall in population mean cho-
lesterol levels in England over the past two decades, and explore any differences between
socioeconomic groups.
Methods and Findings
This is a modelling study based on data from the Health Survey for England. We analysed
changes in observed mean total cholesterol levels in the adult England population between
1991-92 (baseline) and 2011-12. We then compared the observed changes with a counter-
factual ‘no statins’ scenario, where the impact of statins on population total cholesterol was
estimated and removed. We estimated uncertainty intervals (UI) using Monte Carlo simula-
tion, where confidence intervals (CI) were impractical. In 2011-12, 13.2% (95% CI: 12.5-
14.0%) of the English adult population used statins at least once per week, compared with
1991-92 when the proportion was just 0.5% (95% CI: 0.3-1.0%). Between 1991-92 and
2011-12, mean total cholesterol declined from 5.86 mmol/L (95% CI: 5.82-5.90) to 5.17
mmol/L (95% CI: 5.14-5.20). For 2011-12, mean total cholesterol was lower in more de-
prived groups. In our ‘no statins’ scenario we predicted a mean total cholesterol of 5.36
mmol/L (95% CI: 5.33-5.40) for 2011-12. Statins were responsible for approximately 33.7%
(95% UI: 28.9-38.8%) of the total cholesterol reduction since 1991-92. The statin
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Conclusions
Our model suggests that statins explained around a third of the substantial falls in total cho-
lesterol observed in England since 1991. Approximately two thirds of the cholesterol de-
crease can reasonably be attributed non-pharmacological determinants.
Introduction
Cardiovascular disease (CVD) remains the primary cause of death in the UK and globally [1].
However, UK cardiovascular mortality has been falling consistently since the early 1970s [2].
The two main drivers of this fall have been: reductions in cardiovascular risk factor levels; and
improved treatments, both preventive and therapeutic [3].
Serum total cholesterol is one of the main targets for primary and secondary prevention of
CVD. In England, the mean total cholesterol of the population has dropped substantially over
the past three decades [4]. This fall occurred initially as the result of dietary changes alone [5],
but more recently it reflects the interplay between improving diet and increasing statin use [6].
Unlike other cardiovascular risk factors, total cholesterol shows no socioeconomic gradient in
young adults and an inverse gradient at older ages, thus more affluent groups appear to have
higher total cholesterol levels, especially since 1998 [7].
Despite a plethora of information on the effectiveness of statins at the individual level, espe-
cially for secondary prevention, their contribution to the total cholesterol fall in the wider pop-
ulation remains unclear. Farzadfar et al. and Cohen et al. suggest that statins are important in
lowering population mean total cholesterol in high income countries including the United
States (US) [8,9]. However, it seems that this is neither completely true, nor universal because:
1) large falls in total cholesterol occurred before statins were widely used [10,11]; and 2) the
large recent total cholesterol falls observed in Iceland, Sweden, Czech and Finland are princi-
pally attributed to improved diets [12–15]. In addition, there are policy concerns over statins
and health inequalities. This is because statin prescription is a healthcare based intervention,
requiring individual action, which might potentially increase inequalities [16,17].
The debate about statins for primary prevention of CVD has become heated. Last year, the
American College of Cardiology (ACC) and the American Heart Association (AHA) updated
their recommendations for the treatment of total cholesterol, substantially widening the criteria
for statin prescription in otherwise healthy individuals [18]. Now, the UK National Institute
for Health and Care Excellence (NICE) has made similar recommendations to drop the ten-
year annual risk threshold from 20% to 10%, and almost double the number of eligible adults,
from 7 million to 12 million [19]. This has proved very controversial [20,21].
The primary objective of this study was to quantify the contribution of statins to the observed
fall in population mean cholesterol levels in England over the past two decades. A secondary ob-
jective was to look for any differences in this contribution between socioeconomic groups.
Methods
We analysed changes in observed mean total cholesterol levels in the adult England population
between 1991–92 (baseline) and 2011–12. We then compared the observed changes with a hy-
pothetical counterfactual ‘no statins’ scenario, where the impact of statins on population total
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cholesterol was estimated and removed. Therefore, the ‘no statins’ scenario estimates the hypo-
thetical mean cholesterol of the population, if statins were not available and the population had
no benefit from them. Any gap between the observed and the estimated mean total cholesterol
would then be attributed to all other possible drivers of population cholesterol levels, principal-
ly diet. We stratified our analysis by age-group, sex and, where possible and relevant, by quin-
tiles of the 2010 Index of Multiple Deprivation (QIMD) [22].
Survey data
Specifically, we used anonymised, non-identifiable, participant-level data from the Health Sur-
vey for England (HSE) for the two respective periods [23–25]. For the 2011–12 period we ag-
gregated the data of HSE 2011 and HSE 2012, while for 1991–92 this was independently
performed by HSE analysts. These cross-sectional surveys provide a representative sample of
the non-institutionalised population in England for the respective years. The data files con-
tained anonymised, individualised information for all the participants. We excluded partici-
pants younger than 18 years old. For HSE 2011–12 both the weighting and the sampling design
were considered in the estimation of all the point estimates and their standard errors. In partic-
ular, the weighting adjusts both for selection and non-response bias. The sample for HSE
1991–92 was un-weighted, therefore, only the sampling design was taken into account. Further
details about HSE can be found elsewhere [26–28].
Socioeconomic stratification
There were no common socioeconomic indicators between the two samples; QIMD was there-
fore used for the 2011–12 sample and social class based on occupation (I—V) was used for the
1991–92 sample.
QIMD is a measure of relative area deprivation based on the 2010 version of the Index of
Multiple Deprivation [22]. According to this system, all Lower Super Output Areas in England
(LSOA) (average population of 1,500) are ranked in order of increasing deprivation, based on
seven domains of deprivation: income; employment; health deprivation and disability; educa-
tion, skills and training; barriers to housing and services; crime and disorder, and living environ-
ment. For the ranking, individual level information about the habitats of these areas is used from
multiple sources. Then, the QIMD is formed from the quintiles of the above index, one through
five, where quintile one is considered the ‘most affluent’ and quintile five the ‘most deprived’.
The HSE team provided the QIMD of each participant for HSE 2011–12 based on their postcode
of residence, which is a sub-division of LSOAs. We opted to use the QIMD instead of other
available socioeconomic classification systems mainly for three reasons. First, the QIMD was the
only socioeconomic indicator that had no missing cases in our data, second, for our results to be
comparable with other studies that used QIMD and third, because QIMD is extensively used by
local public health departments, Office of National Statistics and researchers in England.
The HSE 1991–92 social class classification was based on the 1990 version of the Standard
Occupational Classification (SOC90) [29] and the self-reported occupation of the participants.
Social class was provided as a variable in the data, by the HSE team. We aggregated full time
students, armed forces personnel, those who never worked, and those whose occupation was
not fully described in one category (‘Other’). In our analysis, we avoided any direct compari-
sons between the two socioeconomic classification systems.
Total cholesterol measurement
Total cholesterol is reported in millimoles per litre (mmol/L). To convert it to milligrams per
decilitre (mg/dL) please multiply the reported cholesterol values by 38.6. In 2011–12 a sub-
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sample of the total HSE sample was eligible and consented to provide non-fasting blood sam-
ples for the measurement of total cholesterol in serum. For HSE 1991–92, participants aged 18
and over were asked to provide a blood sample for the same purpose. Since April 2010 the
equipment that was used for the measurement of total cholesterol for HSE was replaced. The
effect of this change was that measured concentrations of total cholesterol from this date on-
wards were on average 0.1mmol/L higher. We adjusted for this difference in our analyses by
subtracting 0.1mmol/L from the respective total cholesterol measurements. A more detailed
description of the total cholesterol measurement process can be found elsewhere (pages 32–36
in [26], and pages 31–35 in [27]).
Estimating statin utilisation
In England, individuals may have access to statins using two available routes. Statins can either
be prescribed to them by a doctor (or a non-medical prescriber), or they can be bought over
the counter (OTC) from a pharmacy with or without prior expert advice. HSE assessed both
routes. In 2011–12, during a nurse interview, the participants were asked to report the medica-
tion that had been prescribed to them by a doctor or by a non-medical prescriber. Specifically
for statins, they were also asked whether they bought OTC. Finally, those that had been pre-
scribed a statin or bought it OTC were asked if they had used it during the past seven days. We
only considered the participants that answered positively in the last question as statin users.
For HSE 1991–92 the participants were asked similar questions during the nurse interview.
However, statins were included in the wider category of lipid-lowering medication and were
not prescribed for primary prevention [30,31]. Since the uptake of this category as a whole was
very low, we assumed that statins had a negligible effect on total cholesterol at population level;
thus, we ignored it completely (please see S1 Text for further justification of this assumption).
Statistical analysis
The analysis was performed in R statistical software (v3.1.0) [32] including the R package “sur-
vey” [33]. An approximate 95% confidence interval (CI) for proportions (e.g. statin uptake)
was calculated from the survey data using the incomplete beta function method, with an effec-
tive sample size based on the estimated variance of the proportion [34]. Missing cases were ex-
cluded from our analysis (please refer to Table 1).
To test the statistical significance of socioeconomic trends in total cholesterol, against the
null hypothesis of ‘no trend’, we fitted a generalised linear model, with inverse-probability
weighting and design-based standard errors. Specifically, we treated total cholesterol measure-
ments as the dependent variable and the QIMD (or social class) as the independent one. We
considered QIMD and social class as numeric variables for this (e.g. QIMD 1 through 5 repre-
sented the 5 quintiles and social class 1 through 7 represented the social classes I, II, IIIN, IIIM,
IV, V and ‘Other’ respectively). Therefore, the β coefficient (slope) of the QIMD (or social
class) and its standard error was a measure of the socioeconomic gradient. When β was not sta-
tistically significant we assumed no socioeconomic gradient. When β was statistically signifi-
cant, its sign revealed the direction of the gradient (e.g. a negative sign means that mean total
cholesterol is lower among the more deprived groups) and its absolute value measured the
magnitude of the gradient.
A similar approach was followed to explore socioeconomic trends in statin utilisation. Since
this time the dependent variable was a binary one, we used a binomial model.
Estimating the effect of statins. The average effect of each specific statin and strength on
an individual’s total cholesterol is known from the literature [35–38]. However, the exact type
of statin, and strength, had not been recorded for the participants in HSE 2011–12. To
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overcome this limitation we used the exact amount of statins (by proprietary name and
strength) that were both prescribed and dispensed in England for 2011 and 2012, available
from the Health and Social Care Information Centre [39,40]. We then estimated a weighted
mean of the proportional decrease of total cholesterol attributable to statins overall (Eq 1).
Ew ¼
X
i
X
j
ðMij  EijÞX
i
X
j
ðMijÞ
ð1Þ
Eq 1. Formula for the estimation of the proportional decrease in mean total cholesterol at-
tributable to overall statins use.
Where:
Ew is the proportional decrease in mean total cholesterol attributable to statins, among
statin users
Eij is the proportional decrease in mean total cholesterol attributable to a specific statin i of a
specific strength j (e.g. Simvastatin 20mg)
Mij is the number of units of a specific statin i and strength j that have been prescribed and
dispensed. For liquid forms 5ml were considered as one unit, otherwise one tablet was consid-
ered as a unit
For the estimation of Eij data from several meta-analysis were used as follows: We obtained
the mean and standard error (calculated directly from the 95% CI assuming approximate
Table 1. Samples baseline characteristics. Values are numbers (percentages).
Number of participants
interviewed by a nurse
Number of participants with a valid
total cholesterol result
1991–92 (n = 7043) 2011–12 (n = 10965) 1991–92 (n = 4995) 2011–12 (n = 7772)
Characteristics Men Women Men Women Men Women Men Women
Age (years)
18–34 999 (14.2) 1165 (16.5) 877 (8.0) 1350 (12.3) 733 (14.7) 730 (14.6) 604 (7.8) 797 (10.3)
35–54 1148 (16.3) 1240 (17.6) 1632 (14.9) 2194 (20.0) 886 (17.7) 921 (18.4) 1216 (15.6) 1633 (21.0)
55+ 1101 (15.6) 1390 (19.7) 2254 (19.7) 2658 (24.2) 806 (16.1) 919 (18.4) 1611 (20.7) 1911 (24.6)
QIMD
1 (most afﬂuent) - - 1058 (9.6) 1389 (12.7) - - 785 (10.1) 995 (12.8)
2 - - 1057 (9.6) 1364 (12.4) - - 791 (10.2) 997 (12.8)
3 - - 1017 (9.3) 1278 (11.7) - - 732 (9.4) 892 (11.5)
4 - - 865 (7.9) 1133 (10.3) - - 606 (7.8) 781 (10.0)
5 (most deprived) - - 766 (7.0) 1038 (9.5) - - 517 (6.7) 676 (8.7)
Social class
I Professional 235 (3.3) 53 (0.8) - - 174 (3.5) 41 (0.8) - -
II Managerial technical 908 (12.9) 856 (12.2) - - 688 (13.8) 610 (12.2) - -
IIIN Skilled non-manual 320 (4.5) 1304 (18.5) - - 238 (4.8) 909 (18.2) - -
IIIM Skilled manual 1085 (15.4) 388 (5.5) - - 816 (16.3) 251 (5.0) - -
IV Semi-skilled manual 460 (6.5) 693 (9.8) - - 343 (6.9) 464 (9.3) - -
V Unskilled manual 157 (2.2) 363 (5.2) - - 112 (2.2) 225 (4.5) - -
Other 83 (1.2) 138 (2.0) - - 54 (1.1) 70 (1.4) - -
The difference between the number of participants that had a nurse interview and those who had a valid total cholesterol result indicates the missing
cases. QIMD denotes quintiles of index of multiple deprivation (1 = most afﬂuent, 5 = most deprived).
doi:10.1371/journal.pone.0123112.t001
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normality) of the proportional reduction in serum low-density lipoprotein (LDL) from the
meta-analysis of Law et al. [35]. The proportional reduction was derived from the absolute re-
duction, standardised to usual serum LDL of 4.8 mmol/L before treatment, and it was indepen-
dent of the pre-treatment LDL. This allowed us to use a weighted mean approach on
proportions. We then converted the LDL reduction into total cholesterol reduction using data
from other studies, [36–38] assuming a linear relation between total cholesterol and LDL re-
duction. For strengths not included in the above meta-analysis (e.g. Atorvastatin 30mg), we
used a linear regression model to estimate their effect, based on the effect of known strengths.
Specifically, we treated the total cholesterol reduction as the dependent variable and the natural
logarithm of strength as the independent one. We weighted the model against the inverse vari-
ance of the cholesterol reduction. The effectiveness of solid and liquid forms was considered
equal. Similarly, the effectiveness of the combined forms of simvastatin with ezetimibe was
considered equal to the effectiveness of same strength simvastatin (S1 Table). The standard
error of Ew was estimated using the Cochran’s definition for the standard error of the weighted
mean [41,42].
For the ‘no statins’ scenario, we calculated the predicted total cholesterol for each statin
user, with the effect of statin removed using the formula below (Eq 2).
TCpred ¼
TCobs
1 Ew
ð2Þ
Eq 2. Formula for the calculation of predicted total cholesterol with the effect of
statins removed.
Where:
TCpred is the predicted total cholesterol of the statin user with the statin effect removed
TCobs is the observed total cholesterol of the statin user
Ew is the proportional decrease in mean total cholesterol attributable to statins, derived
from Eq 1.
We used Monte Carlo simulation to incorporate the uncertainty from the sampling distri-
bution of Ew. For each statin user we drew 1000 values from a normal distribution with mean
Ew and standard deviation as per the estimated standard error (described above). We then av-
eraged over the TCpred predictions and considered this mean value as the predicted total choles-
terol of each statin user, with the statin effect removed.
Quantifying the contribution of statins on population’s mean total cholesterol reduc-
tion. To quantify and compare the contribution of statins against the contribution of all other
total cholesterol lowering interventions in the population, we first plotted the mean total cho-
lesterol for 1991–92, 2011–12 and the ‘no statins scenario’ by age for each sex. We considered
the area enclosed by the respective curves for 1991–92 and 2011–12 as representing the full ob-
served cholesterol reduction (area A). Therefore, the area enclosed by the 2011–12 and the ‘no
statin’ scenario represents the reduction of cholesterol attributable to statins (area B). Thus, the
fraction (area B) / (area A) expresses the contribution of statins to the observed decline of
mean total cholesterol. For the estimation of areas A and B we used natural spline interpolation
as implemented in the R package “MESS” [43].
To estimate the uncertainty intervals (UI) around the estimated contribution of statins, we
modified the previous method to allow for a Monte Carlo simulation approach. Specifically,
for each age in the population, we drew 10000 values from the conditional sampling distribu-
tion, which we approximated by a normal distribution with age-specific estimate mean and
standard error. These are then averaged across the age range to yield a point estimate, and 2.5%
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and 97.5% percentiles were used to define the 95% UI. Due to small representation of ages
above 89 in our sample, we aggregated participants older than 89 years with those aged 89.
Finally, we repeated the analysis separately for each QIMD under the assumption that total
cholesterol had no socioeconomic gradient in 1991–92. We further limited the analysis in par-
ticipants younger than 76 years because of the small number of older participants in our sam-
ple, when stratified by QIMD. To test the statistical significance of any observed
socioeconomic trend we used the two-tailed Cochran-Armitage trend test.
Sensitivity analysis. For the estimation of Ew several assumptions were involved that do
not necessarily reflect on its estimated standard error. We repeated our analysis after we multi-
plied the standard error of Ew by a factor of 10 in order to test the robustness of our results
with a higher than measured uncertainty scenario.
Ethical approval
Ethical approval for the 2011 and 2012 surveys was obtained from the Oxford A Research Eth-
ics Committee (reference numbers 10/H0604/56) by the Health Survey for England team. For
1991 and 1992 surveys ethical approval had been granted by the Local Research Ethics Coun-
cils in England. Anonymised, non-identifiable data of HSE are available to academics and pub-
lic sector staff through the UK Data Archive (www.data-archive.ac.uk) for secondary analysis,
without requiring further approval.
Results
The baseline characteristics of the 1991–92 and 2011–12 samples are summarised in Table 1,
while mean total cholesterol values by age group and sex are presented in Table 2 (1991–92)
and Table 3 (2011–12). Overall, the prevalence of statin use in England, including OTC statin
Table 2. Observedmean total cholesterol (mmol/L) overall, and by age group, sex and social class in England, 1991–92.
18–34 (years) 35–54 55+
Social class Men Women Men Women Men Women Overall
I Professional 5.52 (5.20 to
5.83)
5.10 (4.70 to
5.50)
5.95 (5.71 to
6.19)
5.64 (5.26 to
6.03)
5.99 (5.66 to
6.31)
6.62 (6.12 to
7.12)
5.64 (5.48 to
5.81)
II Managerial
technical
5.25 (5.06 to
5.44)
5.05 (4.93 to
5.17)
6.01 (5.89 to
6.13)
5.57 (5.46 to
5.69)
6.24 (6.10 to
6.39)
6.79 (6.62 to
6.97)
5.69 (5.58 to
5.82)
IIIN Skilled non-
manual
5.24 (5.06 to
5.43)
5.02 (4.92 to
5.12)
6.15 (5.88 to
6.41)
5.71 (5.58 to
5.83)
6.08 (5.81 to
6.36)
6.80 (6.66 to
6.94)
5.64 (5.49 to
5.79)
IIIM Skilled manual 5.16 (5.04 to
5.27)
5.05 (4.81 to
5.29)
5.93 (5.78 to
6.07)
5.97 (5.70 to
6.24)
6.06 (5.95 to
6.18)
6.83 (6.61 to
7.05)
5.72 (5.61 to
5.84)
IV Semi-skilled
manual
5.16 (4.95 to
5.37)
5.12 (4.96 to
5.27)
5.89 (5.68 to
6.11)
5.70 (5.53 to
5.87)
6.00 (5.82 to
6.19)
6.95 (6.76 to
7.14)
5.70 (5.55 to
5.85)
V Unskilled manual 5.25 (4.82 to
5.68)
5.15 (4.84 to
5.45)
6.07 (5.67 to
6.47)
6.00 (5.77 to
6.22)
6.04 (5.63 to
6.45)
6.97 (6.54 to
7.41)
6.00 (5.79 to
6.21)
Other 4.70 (4.39 to
5.01)
5.14 (4.82 to
5.46)
5.82 (5.03 to
6.61)
5.03 (4.48 to
5.57)
6.37 (5.62 to
7.13)
6.70 (6.14 to
7.26)
5.27 (5.06 to
5.49)
All 5.20 (5.12 to
5.27)
5.06 (5.00 to
5.13)
5.97 (5.90 to
6.05)
5.70 (5.64 to
5.77)
6.10 (6.03 to
6.18)
6.84 (6.76 to
6.93)
Slope of the trend -0.07 (-0.13 to
-0.01)
0.02 (-0.02 to
0.07)
-0.02 (-0.07 to
0.03)
0.05 (0.00 to
0.10)
-0.04 (-0.10 to
0.02)
0.04 (-0.04 to
0.11)
0.00 (-0.02 to
0.02)
P for trend 0.01 0.27 0.47 0.03 0.19 0.32 0.96
Socioeconomic trends are also presented. Brackets contain 95% conﬁdence intervals. The ‘Overall’ column is adjusted for age and sex.
doi:10.1371/journal.pone.0123112.t002
Contribution of Statins to the Cholesterol Decline in England
PLOS ONE | DOI:10.1371/journal.pone.0123112 April 9, 2015 7 / 18
users was 13.2% (95% CI: 12.5% to 14.0%) in 2011–12. Another 0.8% (95% CI: 0.6% to 1.0%)
of the population were prescribed or bought OTC statins; however, they did not use them for
at least a week before the nurse interview.
For 1991–92, statin use was not specifically recorded in the survey; however, the prevalence
of all lipid lowering medications, including statins, was 0.5% (95% CI: 0.3% to 1.0%). Table 4
summarises the prevalence of statin use in England for 2011–12 by age group, sex and QIMD.
There was a statistically significant socioeconomic gradient in ages above 35 years for both
sexes, where the use of statins increased with deprivation.
In 2011–12, some 13.1% (95% CI: 12.4 to 14.0%) of study population used statins prescribed
to them (not including OTC users), over the seven days before the survey interview. We esti-
mated the expected number of units (e.g. tablets or 5ml doses of liquid statins) that were con-
sumed in England for the same period, assuming that they stayed on statins for the whole year
and that institutionalised population shares the same consumption attitudes, to be
Table 3. Observedmean total cholesterol (mmol/L) overall, and by age group, sex and quintiles of index of multiple deprivation (QIMD) (1 = most
affluent, 5 = most deprived) in England, 2011–12.
18–34 (years) 35–54 55+
QIMD Men Women Men Women Men Women Overall
1 (most afﬂuent) 4.80 (4.60 to
5.00)
4.76 (4.60–4.92) 5.53 (5.42 to
5.64)
5.24 (5.13 to
5.36)
5.12 (5.01 to
5.23)
5.77 (5.67 to
5.87)
5.19 (5.09 to
5.29)
2 4.71 (4.56 to
4.86)
4.46 (4.31 to
4.61)
5.47 (5.33 to
5.61)
5.19 (5.08 to
5.31)
5.07 (4.95 to
5.19)
5.72 (5.61 to
5.82)
5.09 (4.99 to
5.20)
3 4.63 (4.41 to
4.86)
4.70 (4.53 to
4.87)
5.64 (5.50 to
5.79)
5.26 (5.15 to
5.38)
5.05 (4.91 to
5.18)
5.67 (5.54 to
5.80)
5.10 (4.99 to
5.22)
4 4.84 (4.65 to
5.02)
4.61 (4.46 to
4.77)
5.46 (5.30 to
5.62)
5.35 (5.20 to
5.49)
4.95 (4.80 to
5.11)
5.55 (5.40 to
5.70)
5.05 (4.94 to
5.17)
5 (most
deprived)
4.79 (4.57 to
5.01)
4.59 (4.44 to
4.74)
5.40 (5.24 to
5.57)
5.31 (5.17 to
5.45)
4.74 (4.55 to
4.92)
5.34 (5.15 to
5.54)
4.93 (4.82 to
5.05)
All 4.75 (4.66 to
4.84)
4.62 (4.55 to
4.69)
5.50 (5.44 to
5.57)
5.26 (5.21 to
5.32)
5.02 (4.96 to
5.08)
5.64 (5.58 to
5.70)
Slope of the
trend
0.02 (-0.05 to
0.08)
-0.01 (-0.06 to
0.04)
-0.03 (-0.07 to
0.02)
0.03 (-0.01 to
0.07)
-0.08 (-0.12 to
-0.03)
-0.10 (-0.14 to
-0.05)
-0.03 (-0.05 to
-0.01)
P for trend 0.60 0.67 0.26 0.16 <0.001 <0.001 0.002
Socioeconomic trends are also presented. The ‘Overall’ column is adjusted for age and sex. Brackets contain 95% conﬁdence intervals.
doi:10.1371/journal.pone.0123112.t003
Table 4. Prevalence of statin use in England 2011–12 by age, sex and quintiles of index of multiple deprivation (QIMD) (1 = most affluent, 5 = most
deprived).
18–34 (years) 35–54 55+
QIMD Men Women Men Women Men Women Overall
1 (most afﬂuent) 0% (0–2%) - 5% (3–8%) 2% (1–3%) 36% (32–41%) 20% (16–23%) 19% (16–23%)
2 - - 7% (4–11%) 3% (2–5%) 38% (34–43%) 24% (20–27%) 22% (18–26%)
3 0% (0–2%) 0% (0–2%) 7% (5–11%) 2% (1–4%) 32% (28–37%) 29% (25–33%) 20% (16–24%)
4 1% (0–5%) - 8% (5–12%) 4% (2–6%) 39% (34–44%) 29% (25–34%) 20% (17–24%)
5 (most deprived) - 1% (0–3%) 9% (6–13%) 8% (5–11%) 47% (40–54%) 34% (29–40%) 21% (17–25%)
All 0% (0–1%) 0% (0–1%) 7% (6–9%) 4% (3–4%) 38% (36–40%) 26% (25–28%)
P for trend - - 0.03 < 0.001 0.04 <0.001 <0.001
The ‘Overall’ column is adjusted for age and sex. Brackets contain 95% conﬁdence intervals.
doi:10.1371/journal.pone.0123112.t004
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approximately 4.00 billion. This showed reassuringly close agreement with the observed unit
consumption of almost 4.07 billion [39,40], being just 1.5% lower.
The mean total cholesterol of adult non-institutionalised population in England decreased
from 5.86 mmol/L (95% CI: 5.82 to 5.90) in 1991–92 to 5.17 mmol/L (95% CI: 5.14 to 5.20) in
2011–12. The decrease was observed in all age groups and it was steeper for ages over 55 for
women and 35 for men (Fig 1). The inverse socioeconomic gradient observed since 1998 [7]
persisted overall and in the subgroup of those aged over 55 years. No gradient was observed for
other age groups (Table 3). On the contrary, we did not observe any socioeconomic gradient in
1991–92 with social class as a socioeconomic indicator when adjusted for age and sex
(Table 2). The trend remained non-significant even when we placed the ‘Other’ social class
group before all other groups.
‘No statins’ scenario
We estimated the total effect of statins on total cholesterol reduction using Eq 1 as Ew = 25.7%
(95% CI: 23.3% to 28.0%). The mean predicted total cholesterol TCpred of the population was
calculated to be 5.36 mmol/L (95% CI: 5.33 to 5.40).
Fig 2 depicts the predicted mean total cholesterol of the population without the effect of
statins, against the observed mean total cholesterol in 1991–92 and 2011–12, by age and sex.
When the effect of statins was removed, the inverse socioeconomic gradient of cholesterol in
the overall population disappeared (slope -0.01, 95% CI: -0.03 to 0.01, P = 0.45). Subgroup
analysis revealed that for men over 55 the slope was reduced to -0.05 (95% CI: -0.10 to -0.01,
P = 0.03) and for women over 55 the gradient was essentially zero (slope -0.04, 95% CI: -0.08 to
0.01, P = 0.09). In addition, a socioeconomic trend appeared for women between 35 and 54
years with a slope of 0.05 (95% CI: 0.01 to 0.10, P = 0.01). We saw no other statistically signifi-
cant gradient, for the remaining age groups (S2 Table).
Finally, statins were estimated as responsible for approximately 33.7% (95% UI: 28.9% to
38.8%) of the total cholesterol reduction since 1991–92. When stratified by sex statins contri-
bution was 40.1% (95% UI: 33.6% to 47.7%) in men and 28.6% (95% UI: 22.3% to 35.0%) in
women. Table 5 summarises the contribution of statins for each socioeconomic group, by age
group and sex. The negative values in the UI, implying that statins could have increased choles-
terol to some, are an artefact of the Monte Carlo simulation due to wide mean cholesterol CI
overlapping in some ages. Statins’ contribution was consistently higher among men, consistent
with the observed higher utilisation.
Sensitivity analysis
The mean predicted total cholesterol (TCpred) of the population, using the inflated standard
error of Ew, was calculated to be 5.39 mmol/L (95% CI: 5.35 to 5.42). This is less than a 0.03
mmol/L difference from the main analysis. For the subgroup of deprived men older than 55,
with the highest statin utilisation, the TCpred from the sensitivity analysis was 0.09 mmol/L
higher than the one from the main analysis. Similarly, the contribution of statins to the ob-
served cholesterol decline for the whole population was estimated to be 33.9% (95% UI: 28.8 to
38.7%), a 0.2% difference from the main analysis result. A similar pattern of minimal changes
was observed for the remaining results.
Discussion
This is the first study we know of to quantify the contribution of statins to the observed de-
crease of total cholesterol in England’s population by socioeconomic group. Our results strong-
ly suggest that the statins were not the main driver of total cholesterol reduction since 1991–92.
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In fact, only around one third of the overall reduction might be attributed to statins, and that
was mainly in patients aged over 55 years. Statins were more widely used in deprived than af-
fluent areas. They appeared to help reduce socioeconomic inequalities in total cholesterol
among women, but not among men.
Fig 1. Mean serum total cholesterol (mmol/L) observed decline in England from 1991–92 to 2011–12 in men and women by age group. The error
bars depict 95% confidence interval of the means. The vertical axis starts at 3 mmol/L to improve readability. The dotted lines are visual aids and do not
reflect linear fits.
doi:10.1371/journal.pone.0123112.g001
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Statins utilisation
In our study, statins’ utilisation was higher in more deprived areas for men and women aged
over 35 years. This socio-economic pattern may partly reflect the higher prevalence of CVD in
more deprived areas [44] and the incentivised use of the QRISK score for cardiovascular risk
Fig 2. Mean serum total cholesterol by age, in men and women, in England (observed and predicted values). The points depict the mean total
cholesterol and the vertical lines 95% confidence intervals (CI). The curves were derived from weighted local regressions and are used to enhance
readability. Due to small sample sizes we aggregated participants aged 89 with those older than 89 years. To improve readability the axes are not numbered
from 0.
doi:10.1371/journal.pone.0123112.g002
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stratification in clinics, which includes area deprivation as a risk factor [45,46]. Our findings
are consistent with earlier studies that used different methodologies. Ashworth et al. and Wu
et al. also found that statin prescription was higher in more deprived areas in the UK [47,48].
This success in tackling inequalities might be attributed to the National Health Service (NHS),
since evidence from Australia, Sweden, Denmark and the US [49–52] suggest that statin pre-
scription in these countries has a socioeconomic gradient, with a less than expected utilisation
among the more disadvantaged, and potentially increases health inequalities.
Statins contribution to cholesterol decline
The second interesting finding is the contribution of statins to the observed decline of total cho-
lesterol since 1991–92. We found that statins are not the main driver of the cholesterol decline
in England, echoing studies from Iceland, Sweden, Finland and the Czech Republic [12–15]. We
estimated that only about a third of the observed total cholesterol decline could be attributed to
statins. This contribution was slightly higher than the aforementioned studies, perhaps reflect-
ing a more recent time period with correspondingly higher statin use in England 2011–12, and
possible nuanced differences in methodologies. While the cholesterol decrease was observed in
all age groups since 1991, statins mostly contributed to the fall in people older than 55 years.
The observed inverse socioeconomic gradient in total cholesterol levels might be partly at-
tributed to statins. In the ‘no statins’ scenario the gradient disappeared completely when all
ages were considered. However, the statin contribution varied across different genders and so-
cioeconomic groups. Statin utilisation was higher in the most deprived groups, but inequitable
by gender, reaching barely one third in women (34%) but almost half (47%) of deprived men
in the 55+ age group. This difference can only partly be explained by the higher CVD preva-
lence among men. By contrast, the statin contribution to cholesterol lowering was rather stable
across socio-economic groups in men (some 33%), but rose from 16% to 33% in women. This
suggests that the component of all other cholesterol reduction drivers had a higher impact
among the most deprived men, while their effect among women of all socioeconomic back-
ground was more or less equal. This demands further research.
Table 5. Estimated proportional contribution of statins to total cholesterol reduction since 1991–92 for each quintile of index of multiple depriva-
tion (QIMD), by age group and sex.
35–54 (years) 55–75 18–75
QIMD Men Women Men Women Men Women
1 (most afﬂuent) 14.0% (-19.2 to
41.9%)
4.2% (-24.4 to
28.3%)
50.6% (36.2 to
64.6%)
24.4% (11.4 to
36.6%)
33.5% (15.6 to
49.9%)
15.9% (1.9 to
28.9%)
2 13.0% (-28.2 to
45.9%)
5.9% (-23.9 to
30.7%)
59.7% (43.5 to
75.7%)
23.9% (10.2 to
36.8%)
36.0% (19.5 to
51.2%)
14.3% (2.0 to
25.5%)
3 17.9% (-49.7 to
78.2%)
3.6% (-33.9 to
33.3%)
37.8% (21.3 to
52.7%)
36.0% (21.2 to
50.1%)
26.9% (7.3 to
44.6%)
23.5% (7.5 to
37.5%)
4 29.0% (-7.2 to
58.9%)
19.3% (-37.9 to
64.4)
45.0% (27.7 to
60.6%)
36.3% (21.3 to
50.5%)
34.4% (19.0 to
48.9%)
24.8% (9.2 to
38.9%)
5 (most
deprived)
31.1% (-9.1 to
63.8%)
37.1% (-19.0 to
79.9%)
43.2% (28.6 to
57.1%)
32.6% (16.0 to
47.9%)
33.8% (19.7 to
46.1%)
33.4% (18.3 to
47.5%)
All 22.2% (4.8 to
39.8%)
11.9% (-4 to 26.1%) 48.0% (40.1 to
56.1%)
40.0% (23.3 to
54.9%)
33.2% (25.8 to
40.6%)
21.3% (14.8 to
28.0%
P for trend 0.24 0.03 0.41 0.17 0.99 0.02
Age group 18–34 was omitted as statins’ contribution was practically zero. Analysis was restricted to ages younger than 76 due to low number of older
participants. Brackets contain 95% uncertainty intervals estimated by Monte Carlo.
doi:10.1371/journal.pone.0123112.t005
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Public health implications
Overall, our research supports the principle of statins being the second best option for primary
prevention. Non-statin interventions account for two thirds of the total cholesterol reduction
observed since 1991–92, which can be mostly attributed to dietary changes because physical ac-
tivity levels have not increased substantially over this period [30,53] and the contribution of
other factors affecting lipids is small and remained more or less stable. Indeed, United Nations
Food and Agriculture Organization data indicate that the animal fat supply per capita in the
UK has fallen by almost 25% since 1991 [54]. This echoes Rose’s original assertion that the
greatest public health impact will be achieved through population-wide reductions in CVD
risk than through interventions targeting high-risk individuals [55].
Furthermore, the recent proposed widening of criteria for statin prescription in primary pre-
vention by the ACC/AHA [18] and NICE [19] has been questioned on grounds of effectiveness,
cost-effectiveness, acceptability and safety [21]. These measures may prove to be less effective
than anticipated because of cumulative attrition factors. Approximately half of the UK patients
that are commenced on lipid lowering medication for primary prevention are ineligible accord-
ing to the respective guidelines, while many eligible patients remain untreated [48]. Moreover,
over half the patients commenced on statins for primary prevention have discontinued them
within 1–2 years [56–59]. In addition to medicalising otherwise healthy individuals, some pa-
tients may also be tempted to adopt more unhealthy diets because of the false ‘reassurance’ that
statins will compensate for the unhealthy behaviours [60]. Along with the increased resource re-
quirements, an additional opportunity cost comes from undermining the primary driver of cho-
lesterol decline—nutritional improvements at individual and national policy levels [61].
Regarding inequalities in health and inequities in care: our research suggests that English
statin prescribing might be equitable. This represents a success for the socialised medicine pro-
vided by the NHS England. In contrast, statin-based cholesterol reduction was not equitable
among men, being similar in the more affluent and more deprived groups. These results are in-
triguing, because healthcare-based interventions generally increase the inequality gap [16,17].
Strengths and limitations
This study was grounded on the best available evidence to explore the research question. We
integrated all the available data from HSE, a cross-sectional survey of very high quality, the Pre-
scription Cost Analysis report, an accurate and precise report about prescriptions in England,
and published meta-analyses on the effect of statins. The modelling approach allowed for the
best use of all the available information. In fact, despite the assumptions regarding the effects
of statins our results were robust to the sensitivity analysis. Any biases and errors were diluted
because they only applied to the about 13% of the sample who were statin users.
However, our study has several limitations. First, it is based on self-reported statin prescrip-
tion and adherence, and does not account for statin indications; however, consistent data from
prescription cost analysis reports for 2011–12 [39,40] suggest that our estimated prevalence of
statin-use is fairly accurate. Second, unlike HSE 2011–12, HSE 1991–92 was not weighted to
adjust for non-response bias. Furthermore, no other HSE has recorded statin use separately
from other lipid-lowering medication; this renders an interim point analysis between 1991 and
2011 practically impossible.
Third, there were no common or directly compatible socioeconomic indicators between the
two surveys to allow for more accurate comparisons. Our assumption that there was no socio-
economic gradient of mean total cholesterol in 1991–92 is supported by our finding of no such
gradient by social class in HSE 1991–92. This is consistent with Scholes et al. who also showed
no socioeconomic gradient in 1994 using QIMD as socioeconomic indicator [7]. The Whitehall
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II cohort also showed no socioeconomic gradient for total cholesterol in 1985–88 [62]. Neither
did our analysis consider other inequalities, for instance, ethnic minorities or people with men-
tal health or illiteracy problems [47,63,64].
Fourth, the estimate of the statin effect Ew was derived mostly from short-term trials lasting
less than one year. However, Edward et al. have shown that the statins effect remains fairly sta-
ble in trials lasting more than one year (Additional file 5 in [37]). In addition, the estimation of
Ew assumes that the differences between each trial population and our study sub-population of
statin users were the same for each statin.
Fifth, this analysis cannot fully control for other factors that interfere with lipid profiles and
their prevalence in the population changed substantially over the last two decades. BMI and di-
abetes mellitus are possibly the most important of them.
Finally, we used the statins effects reported in clinical trials, acknowledging that this might
overestimate the real world efficacy of these drugs (mostly because of selection bias in the trials
and reduced compliance in the population). However, this result in an overestimation of the
contribution of statins, and thus its real contribution might have been even less than one third.
Conclusions
Our research suggests that statins contributed about one third of the observed total cholesterol
decline in England since 1991–92, and that their impact on reducing socioeconomic inequali-
ties in total cholesterol was generally positive. However, the proposed wider indications for
statins in primary prevention remains contested.
Further research is now needed to quantify the potential contribution of primary prevention
statins to the ‘hard’ outcomes of cardiovascular morbidity and mortality in the UK. There is
sufficient current evidence, however, to justify reconsidering the priorities of different interven-
tions for the primary prevention of CVD.
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